10-Q: Amgen Reports Q3 2024 Results: Revenue Growth Driven by Horizon Acquisition and Key Products

Amgen's Q3 2024 results show a significant increase in revenue, primarily driven by the acquisition of Horizon Therapeutics and strong performance from key products, though operating expenses also rose substantially.

Summary

• Amgen's total revenue for the third quarter of 2024 reached $8.503 billion, a 23% increase compared to $6.903 billion in the same period last year.
• Product sales were the main driver, increasing by 24% to $8.151 billion, up from $6.548 billion in Q3 2023.
• The increase in product sales was primarily due to a 29% increase in volume, partially offset by a 2% decline in net selling price.
• Operating expenses also increased significantly, rising by 32% to $6.456 billion, compared to $4.882 billion in Q3 2023.
• Net income for the quarter was $2.830 billion, a substantial increase from $1.730 billion in the same quarter of the previous year.
• Diluted earnings per share (EPS) increased to $5.22, up from $3.22 in Q3 2023.
• For the nine months ended September 30, 2024, total revenue was $24.338 billion, a 22% increase from $19.994 billion in the same period of 2023.
• Product sales for the nine-month period were $23.310 billion, a 22% increase from $19.077 billion in 2023.
• Net income for the nine-month period was $3.463 billion, a decrease from $5.950 billion in the same period of 2023.
• Diluted EPS for the nine-month period was $6.40, down from $11.06 in the same period of 2023.
• The company's cash and cash equivalents stood at $9.011 billion as of September 30, 2024, down from $10.944 billion at the end of 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong revenue growth and positive results from the Horizon acquisition, but concerns remain about increasing operating expenses, declining net income for the nine-month period, and ongoing legal and regulatory challenges.

Positives

• The acquisition of Horizon Therapeutics has significantly boosted Amgen's revenue and product portfolio.
• Strong volume growth in key products like Repatha, TEZSPIRE, and EVENITY indicates strong market demand.
• The company's net income and diluted EPS showed substantial growth in Q3 2024 compared to the same period last year.
• The company is seeing positive results from its strategic equity investments, particularly in BeiGene.
• Amgen's global operations are showing growth, with both U.S. and ROW sales increasing.

Negatives

• Operating expenses increased significantly, primarily due to the Horizon acquisition, impacting overall profitability.
• Net selling prices for some products have declined, partially offsetting volume growth.
• The company's net income and diluted EPS for the nine-month period decreased compared to the same period last year.
• The company's cash and cash equivalents decreased from the end of 2023.
• ENBREL sales decreased by 20% in Q3 2024, primarily due to unfavorable changes to estimated sales deductions and lower net selling price.

Risks

• Uncertain macroeconomic conditions, including inflation and higher interest rates, pose challenges to the business.
• The company faces ongoing pricing pressures and cost containment measures in the healthcare industry.
• Provisions of the Inflation Reduction Act (IRA) and the 340B Drug Pricing Program are expected to continue to affect the business.
• The company is involved in various legal proceedings and government investigations, which could have a material adverse effect.
• The company is currently under examination by the IRS for the years 2016-2018 with respect to issues similar to those for the 2010 through 2015 period.
• The company faces risks related to cybersecurity and data breaches, which could disrupt operations and expose sensitive data.
• The company's U.S. patent for RANKL antibodies for Prolia and XGEVA expires in February 2025, which could lead to increased competition.
• The company is subject to changing U.S. federal coverage and reimbursement policies, including mandatory price setting under the IRA.
• The company is subject to changing reimbursement and pricing actions in various states, which could negatively affect access to and sales of its products.
• The company is subject to U.S. commercial payer actions that could affect access to and sales of its products.
• The company is subject to government and commercial payer actions outside the United States that could affect access to and sales of its products.

Future Outlook

Amgen expects product sales growth from acquired Horizon products and volume growth from other brands to be partially offset by net selling price declines on a year-over-year basis at a portfolio level for the remainder of 2024. The company intends to continue investing in its business while reducing debt and returning capital to stockholders through dividends and stock repurchases.

Management Comments

• Management believes that existing funds, cash generated from operations, and existing sources of and access to financing are adequate to satisfy the company's needs for working capital, capital expenditure, and debt service requirements.
• Management intends to continue investing in the business while reducing debt and returning capital to stockholders through dividends and stock repurchases.

Industry Context

The report highlights the ongoing challenges in the pharmaceutical industry, including pricing pressures, cost containment measures, and the impact of government regulations like the IRA. The acquisition of Horizon Therapeutics is a strategic move to diversify and strengthen Amgen's portfolio in the face of these challenges. The report also reflects the increasing importance of biosimilars and the competitive landscape in the pharmaceutical market.

Comparison to Industry Standards

• Amgen's revenue growth of 23% in Q3 2024 is above the average growth rate for large-cap pharmaceutical companies, which typically see single-digit growth.
• The company's operating expense increase of 32% is higher than the industry average, reflecting the impact of the Horizon acquisition.
• Amgen's net income growth of 64% in Q3 2024 is significantly higher than the industry average, but the nine-month net income decrease of 42% is a concern.
• The company's focus on volume growth and strategic acquisitions is a common strategy among large pharmaceutical companies to offset pricing pressures.
• Amgen's legal and tax challenges are not unique, as many large pharmaceutical companies face similar issues with regulatory bodies and tax authorities.
• The company's investment in cybersecurity is in line with industry standards, given the increasing threat landscape.

Legal Proceedings

• Amgen is involved in various legal proceedings, including patent litigation related to Repatha, Prolia/XGEVA, and PAVBLU.
• The company is also facing antitrust class actions related to Sensipar and Regeneron.
• Amgen is contesting tax disputes with the IRS in the U.S. Tax Court.
• The company is also involved in securities class action and shareholder derivative litigation.
• Amgen is involved in securities matters related to ChemoCentryx, Inc.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance, dividend payments, and stock repurchases.
• Employees may be affected by the company's financial stability and strategic decisions.
• Customers (healthcare providers and patients) may be impacted by the availability and pricing of Amgen's products.
• Suppliers may be affected by the company's purchasing decisions and financial health.
• Creditors may be impacted by the company's debt levels and ability to repay obligations.

Next Steps

• Amgen will continue to monitor and manage the impact of the IRA and other government regulations.
• The company will continue to invest in its pipeline and strategic acquisitions.
• Amgen will continue to focus on reducing debt and returning capital to stockholders.
• The company will continue to defend its intellectual property rights in ongoing litigation.
• Amgen will continue to monitor and address cybersecurity risks.

Key Dates

Keywords

Amgen, biotechnology, pharmaceuticals, Horizon Therapeutics, revenue, product sales, net income, EPS, operating expenses, clinical trials, regulatory approvals, Repatha, TEZSPIRE, ENBREL, Prolia, XGEVA, TEPEZZA, KRYSTEXXA, Inflation Reduction Act, 340B Drug Pricing Program, cybersecurity, legal proceedings, tax dispute